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PROTECTION AGAINST ISCHEMIA AND
REPERFUSION INJURY

The high volume of cardiac-related surgeries, both elec
tive and emergency procedures and including cardiac
transplants, lead to the above-described problems. Thus,

This application claims the bene?t of US. application
Ser. No. 60/232,093, ?led Sep. 12, 2000.

methods and agents to provide protection against myocardial

FIELD OF THE INVENTION

SUMMARY OF THE INVENTION

The invention relates to compounds protective against
ischemia and reperfusion injury, particularly in the

The invention is directed to agents and a method of using
the agents to reduce the injury associated With ischemia and
reperfusion of organs such as the heart. The compounds are

myocardium, and their use.

ischemia and to avoid post ischemic dysfunction are needed.

10

Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 SEQ ID NO:1,
hereinafter referred to as Deltorphin A, and Tyr-D-Ala-Phe

BACKGROUND

Gly-Tyr-Pro-Ser-Gly-Glu-Ala-Lys-Lys-Ile SEQ ID NO:2,

Tissues deprived of blood and oxygen undergo ischemic
necrosis or infarction With possible irreversible organ dam
age. In some circumstances, hoWever, such as during cardiac

hereinafter referred to as Dermorphin H. Administration of
15

surgery, it is desirable to interrupt the normal myocardial

contractions (cardioplegia) and actually induce ischemia.
Such elective or obligatory ischemia occurs in the presence

of safeguards such as cardioplegia-induced cardiac arrest

and hypothermia. While these safeguards provide consider
able myocardial protection, alteration of myocardial ener
getics (stunning) and poor postoperative ventricular function
still remain signi?cant problems.
Once the How of blood and oxygen is restored to the organ
or tissue (reperfusion), the organ does not immediately
return to the normal preischemic state. Reperfused postis

chemic non-necrotic myocardium is poorly contractile and
has reduced concentrations of high energy nucleotides,
depressed subcellular organelle function and membrane

20

25

35

40

45

Which there are time constraints due to the limits of myo

cardial preservation.
Postischemic dysfunction may be due to a variety of
factors. Oxygen free radicals may play a role, as generation
of free radicals in stunned myocardium has been demon
strated and free radical scavengers have been shoWn to

attenuate contractile dysfunction. Impaired intracellular cal

cium handling and calcium overload during early reperfu
sion may contribute to postischemic dysfunction; While
calcium infusions enhance contractility in both normal and

55

transplant. The isolated organ is exposed to a preservative
solution containing an effective amount of Deltorphin A
SEQ ID NO:1 or Dermorphin H SEQ ID NO:2. The con
centration of Deltorphin A SEQ ID NO:1 or Dermorphin H
SEQ ID NO:2 in the preservative solution for a heart is about
The invention is additionally directed to a method for
reducing effects of an ischemic episode in a mammal by
administering an effective concentration of Deltorphin A
SEQ ID NO:1 or Dermorphin H SEQ ID NO:2 in a phar
maceutically acceptable carrier. Administration is prior to or
substantially concurrently With the onset of ischemia, or one
hour post cerebral ischemia.
The invention is further directed to a composition that
protects a mammalian organ from injury. The composition
contains Deltorphin ASEQ ID NO:1 or Dermorphin H SEQ
ID NO:2, in either a naturally occurring form or a synthe
siZed form.
The invention is also directed to an organ preservative
solution that contains Deltorphin A SEQ ID NO:1 or Der
morphin H SEQ ID NO:2 at a concentration effective to
protect the organ, such as a heart, from ischemic injury.
These and other advantages of the invention Will be

apparent in light of the folloWing draWings and detailed

description.

postischemic myocardium, ischemia as short as a feW min

utes produces an impairment in sarcoplasmic reticulum
calcium transport and a shift of the calcium ATPase activity.
Postischemic myocardium is also associated With reduced

The invention is also directed to a method to prevent
damage to an isolated organ, for example, a heart for

100 pM.

folloWing ischemia, there is only very sloW recovery of
myocardial contractile function. The problems are exacer
bated in high risk patients, such as those With poor preop
erative ventricular function, recent myocardial infarction or
left ventricular hypertrophy. These same problems also
occur during organ storage for cardiac transplant, under

in a pharmaceutically acceptable formulation prior to the
onset of ischemia, for example, 24 hours prior to ischemia.
In other embodiments, Deltorphin A SEQ ID NO:1 or
Dermorphin H SEQ ID NO:2 is administered substantially
concurrently With the onset of ischemia, during an ischemic
episode, or post-ischemia. The formulation may be admin

1—20 mg/kg of body Weight.
30

ible ischemia may depress contractility for days. Studies
con?rm that, despite restoration of myocardial How and a

quick recovery of myocardial oxygen consumption (MVO2)

necrosis and preserves organ function.
In one embodiment, a method of protecting against
ischemia and reperfusion injury in a mammal is disclosed.
An effective concentration of DeltorphinASEQ ID NO:1 or
Dermorphin H SEQ ID NO:2 is administered to the mammal

istered parenterally at a concentration in the range of about

damage that resolves only sloWly. Although reperfusion
restores oxygen and reverses ischemia, repletion of high
energy nucleotides such as adenosine triphosphate (ATP)
and reversal of ischemic membrane damage is sloW, and
contractile function may be profoundly depressed for a long
period. Just minutes of ischemia causes loss of myocardial
systolic Wall thickening for hours. Longer periods of revers

Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID
NO:2, particularly prior to an ischemic event, reduces tissue

BRIEF DESCRIPTION OF THE DRAWINGS
60

FIG. 1 is a histogram shoWing myocardial infarction siZe

concentrations of myocardial high-energy phosphates and

in control and treated animals.

adenine nucleotides, as obligatory reduction in myocardial

FIG. 2 is a histogram shoWing post-ischemic release of
troponin I in control and treated animals.
FIG. 3 is a graph shoWing end diastolic pressure in the left
ventricle of control and treated animals.
FIG. 4 is a graph shoWing functional recovery in control
and treated animals.

ATP content during ischemia occurs as myocytes utiliZe ATP

for maintenance of cellular integrity. Since ATP is essential

for myocardial contraction and relaxation, ATP depletion
may have detrimental effects upon postischemic myocardial
functional recovery.

65
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FIG. 5 is a histogram showing ventricular functional
recovery in control and treated animals.

With an equal volume of 0.9% NaCl. After 24 h, the hearts
from both treated and control animals Were excised and

perfused in a modi?ed Langendorff perfusion apparatus at
37° C. using oxygenated Krebs-Henseleit buffer as the

DETAILED DESCRIPTION

perfusate, as knoWn to one skilled in the art. Coronary
perfusion pressure Was maintained at 700 mm Hg by regu

The invention is directed to compounds that have a

salutary effect on cardiac function following ischemia, and
methods of using the compounds. The compounds may be
administered directly to an individual, and are particularly
effective When administered 24 h prior to the onset of
ischemia. This may occur, for example, prior to scheduled
cardiac surgery. The compounds may also be included in a

lating coronary ?oW. All hearts Were paced at 5.5 HZ (300

beats per minute, bpm) except during ischemia. A saline
?lled balloon Was inserted in the left ventricle to measure
10

Were reperfused for 120 min.
Left ventricles Were isolated and divided into three seg
15

NO:1, hereinafter referred to as deltorphin A. Another of the
compounds is a thirteen amino acid sequence Tyr-D-Ala

Phe-Gly-Tyr-Pro-Ser-Gly-Glu-Ala-Lys-Lys-Ile SEQ ID
NO:2. The peptides may be produced by a number of
methods, such as using an automated peptide synthesiZer,
through recombinant molecular techniques, or isolated from

20

molecular Weight of about 1430.64 daltons. Both Deltorphin

25

adding 100 pM of a solution comprised of ethanol, propy
physiological saline then used to obtain the appropriate
concentration. The initial alkaline pH is adjusted to 7.4 With

of 27:5%, While rats pretreated With Deltorphin A SEQ ID
NO:1 had a reduced mean infarct siZe of 12.95:3.3%, and

rats pretreated With Dermorphin H SEQ ID NO:2 had a
35

reduced mean infarct siZe of 13.5:3.5%.

Speci?c infarct volumes in four separate cross sectional
areas of brains isolated from animals treated post-ischemia

With DeltorphinASEQ ID NO:1 and Dermorphin H SEQ ID

during or even after an ischemic event. For administration

NO:2 are shoWn in Tables 1—3. In each case, six male mice
40

or organ preservation solution, a concentration of about 100

(strain C57) Were subjected to ischemia for one hour and
then received an injection of either 100 pl normal saline

(vehicle), 100 pl of 4.0 mg/kg Deltorphin A SEQ ID NO:1
(Table 2), or 100 pl of 4.0 mg/kg Dermorphin H SEQ ID
NO:2 (Table 3). The dose of DeltorphinASEQ ID NO:1 and

pM is useful.
Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID
NO:2 may be administered directly into a mammal, either
alone or in combination With other substances. Alternatively,

(control, solid bar), in animals treated With Deltorphin A
SEQ ID NO:1 at 2.0 mg/kg (treated, open bar) 24 h prior to

percent of infarct siZe. Control rats had a mean infarct siZe

1 N HCl.

kilogram (mg/kg) is useful. For administration into a tissue

of myocardium. Data Were expressed as mean plus or minus
standard error of the mean (:SEM) and Were analyZed using
a paired Student’s t-Test. Con?dence limits Were established
at 95%.

20 min ischemia and 120 min reperfusion, and animals
treated With Dermorphin H SEQ ID NO:2 at 2.0 mg/kg
(treated, hatched bar) 24 h prior to 20 min ischemia and 120
min reperfusion. Pretreatment of animals With Deltorphin A
SEQ ID NO:1 or Dermorphin H SEQ ID NO:2 decreased the

lene glycol, and 1 N NaOH in a 1:111 ratio, With sterile

into a mammal, a dose of about 1—20 milligrams per

lium chloride, and stored in formalin. Infarct siZe Was
measured on digitiZed images and expressed as a percentage

the infarct siZe in hearts from animals receiving only saline

A SEQ ID NO:1 and Dermorphin H SEQ ID NO:2 are
insoluble in Water or saline, but may be solubiliZed by

Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID
NO:2 that have been solubiliZed may be administered by
parenteral means, for example, intravenous injection. In one
embodiment, administration of Deltorphin A SEQ ID NO:1
is at the time of induced ischemia, but may also be added

ments along their short axis, stained With triphenyltetraZo

The results are shoWn in FIG. 1, Which is a histogram of

a naturally occurring source, as is knoWn to one skilled in the

art. Deltorphin A SEQ ID NO:1 has a molecular Weight of
955.1 daltons, and Dermorphin H SEQ ID NO:2 has a

in mm Hg. After 15 min equilibration, both groups Were

subjected to 20 min Zero-?oW global ischemia, and then

preservative solution for an isolated organ, such as a heart or

liver being maintained viable for transplant.
One of the compounds is a heptapeptide having the
sequence Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 SEQ ID

developed pressure (DP) and end-diastolic pressure (EDP)

45

Dermorphin H SEQ ID NO:2 may be in the range of 1 mg/kg
to 4 mg/kg. Reperfusion folloWed for 24 hours, then animals
Were sacri?ced and 2 mm brain sections from each of four

it may be added as a component of a solution used to

maintain the viability of isolated organs, such as an additive

areas Were evaluated. The total cross section area is the sum

to cardioplegia and other organ preservation solutions. In
one embodiment, Deltorphin A SEQ ID NO:1 and/or Der

of the four cross section areas; likeWise, the total damaged
50

morphin H SEQ ID NO:2 is coadministered as an adjuvant
With other compounds or strategies that are designed to
protect organs from ischemia. As an example, Deltorphin A
SEQ ID NO:1 and/or Dermorphin H SEQ ID NO:2 may be

administered With agents that affect nitric oxide (NO)

synthase, such as arginine hydrochloride. Arginine hydro
chloride is knoWn to prevent the decline in cardiac function

folloWing an ischemic episode.
The folloWing description demonstrates use and ef?cacy
of Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID
NO:2 in a variety of systems.
Perfused Heart
Deltorphin A SEQ ID NO:1 or Dermorphin H SEQ ID
NO:2, at a dose of 2 mg/kg and solubiliZed as described
above, Was administered by tail vein injection into rats

Weighing betWeen about 350—400 g (number of animals
(n)=6). Control rats (n=6) Were injected in the same manner

cross section areas is the sum of the four damaged cross
section areas for each animal.

TABLE 1
Saline (Vehicle) Treated
55
Cross
Section
Area 1
Cross
Section
Area 2
60
Cross
Section
Area 3
Cross
Section
Area 4
65
Total

14.81

14.65

12.55

13.18

15.35

15.9

22.52

22.39

19.52

20.68

22.08

20.22

25.24

25.45

21.84

23.51

24.77

22.69

24.51

24.05

21.54

24.98

23.81

22.73

87.08

86.54

75.45

82.35

86.01

81.54

US 6,900,178 B2

Cross
Section
Area
Damaged
Cross
Section

TABLE l-continued

TABLE 2-continued

Saline (Vehicle) Treated

Deltorphin A Treated
5

6.58

4.49

5.77

5.02

4.83

5.86

Damaged
Cross
Section
Area 4

6.57

10 Damaged
Cross

3.77

Total

Area 1
Damaged

9.7

6.86

7.42

8.21

8.81

Cross
Section
Area2

Section
Area
Damaged

Damaged
Cross
Section

11.86

10.7

10.65

11.79

9.52

8.24

%
15 Corrected
Volume

3.4

7.36

6.74

6.94

7.11

20.1

16.66

29.64

27.28

28.85

27.45

24.09

19.19

36.72

33.58

34.97

33.71

40.2

33.32

59.28

54.56

57.7

54.9

Area 3

Damaged

10.02

12.22

11.03

11.21

10.26

10.76

Cross
Sectlon

For animals receiving Deltorphin A after one hour of
ischemia, the infarct volume Was reduced to about 30%
20 (total damaged cross section area of 149.98, total cross

Are/a4
Total

3816

3427

3487

3623

3342

3143

section are of 496.12, 149.98/496.12=0.302). In all siX

Damaged
Cross

Deltorphin A treated animals, the corrected volume Was
299.96, yielding an infarct volume of 49.99 mm3 (299.96/6),

Sectlon

With a standard deviation of 110,63.

Area

Damaged

43.82

39.60

46.22

44.00

38.86

38.55

87.644

68.54

69.74

72.46

66.84

62.86
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0/0

TABLE 3

Corrected

Volume

Dermorphin H Treated
Cross
_

_

_

_

30

For animals receiving only saline after one hour of
ischemia, the infarct volume Was about 42% (total damaged

Are/a1
Cross
cross section area of 208.38, total cross section area of
iecnozn
1163.
498.97, 208.38/4'98.9'7=0.417). The corrected volume Was
Cross
obtained by multiplying the damaged cross section area by 35 Section
2, since 2 mm sections Were assessed. In all siX control
Are/a3
animals this Was 428.08, yielding an average infarct volume
gross

of 71.35 mm3 (428.08/6), With a standard deviation of

14.92

13.87

14.94

14.65

13.69

14.27

2262

21.52

21.48

22.33

21.66

21.36

235

238

2369

2398

2371

2235

23-8

2124

2159

21-87

22-43

2339

84.84

80.43

81.7

82.83

81.49

81.37

4.5

5.24

3.76

4.25

3.99

3.47

5-41

6-75

5-2

7-13

5-87

5-13

6.43

7.34

4.82

6.77

6.22

5.36

3.45

3.23

3.37

4.62

4.15

3.89

19.79

22.56

17.15

22.77

20.23

17.85

23.33

28.05

20.99

27.49

24.83

21.94

39.58

45.12

34.3

45.54

40.46

35.7

Section

A2211?

18,598.
Total

TABLE 2

40 Cross
Section

.

Area

Deltorphm A Treated

Cross
Section
Area 1
Cross

16.42
22.07

15
22.81

13.89
20.06

Damaged

14.67
21.23

15.23
20.78

14.56

CYOSF

21.34

Secnon
45 Area 1
Damaged

Section
Area 2
Cross

CrOS_S
24.17

25.51

23.52

23.79

24.14

Section
Area 2
Damaged

24.56

Section

Area 3

50 cros_s

Cross
Section
Area 4

20.77

Total
Cross
Section
Area

83.43

86.81

80.71

81.24

82.49

81.44

5.16

4.14

5.09

4.98

5.32

4.76

Damaged

23.49

23.24

21.55

22.34

20.98

Sectlon
Area 3
Damaged
Cross
Sectlon
55 Area 4

Total

Damaged

Cross
Section
Area 1

Damaged
Cross
Section
Area 2
Damaged

6O

748

3.69

586

3.26

7_7

9.49

697

8.59

736

9.23

683

Damaged
%
Corrected
Volume

8.75

Cross

Section
Area3

Cross
Section
Area

_

65

_

_

_

For animals receiving Dermorphln H after one hour of
ischemia, the infarct volume Was reduced to about 24%
(total damaged cross section area of 120.35, total cross

US 6,900,178 B2
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section are of 492.66, 120.35/492.66=0.244. In all siX Der

SEQ ID NO:2. Open squares are from treated animals, and
solid circles are from animals treated With 0.5 ml saline

morphin H treated animals, the corrected volume Was 240.7,
yielding an infarct volume of 40.12 mm3 (240.7/6), With a
standard deviation of 4.652.

(control). FIG. 4 is a graph shoWing percent of functional
recovery during reperfusion of isolated rat hearts after 20

These results are summarized as folloWs.

min ischemia in rats treated 24 h prior to ischemia With 2.0

mg/kg DeltorphinASEQ ID NO: 1 or 2.0 mg/kg Dermorphin
H SEQ ID NO:2. Open squares are from treated animals, and
Treatment

solid circles are from control animals. Differences in recov

Average Infarct
Volume (mm3)

Standard
Deviation

Infarct Volume

71.35
49.99
40.12

8.598
10.63
4.652

42%
30%
24%

Control
Deltorphin A
Dermorphin H

10

reperfusion, as shoWn in FIG. 3. As shoWn in FIG. 4, left
ventricular functional recovery (% recovery of baseline

The data demonstrate the ef?cacy of Deltorphin A and
Dermorphin H treatment post cerebral ischemia.
Pretreatment With Deltorphin A SEQ ID NO:1 and Der
morphin H SEQ ID NO:2 also signi?cantly decreased the
cardiac form of troponin I (cTn-1) values following 20 min

15

ischemia, as shoWn in FIG. 2. An increase in cTn-1, a protein

20

As shoWn in FIG. 5, left ventricular functional recovery

Was signi?cantly improved in Deltorphin A SEQ ID NO:1
25

SEQ ID NO:2 treated animals and control animals Was about

the same (about 51%).
These results shoW that in a normoXic, isolated perfused
rat heart preparation, administration of Deltorphin ASEQ ID
NO:1 and Dermorphin H SEQ ID NO:2 confers cardiopro
tection When administered either prior to planned ischemia
or post ischemia. The salutary effects on the post-ischemic
35

reperfusion of isolated rat hearts after 20 min ischemia in
rats pretreated 24 h prior to ischemia With 2.0 mg/kg
Deltorphin A SEQ ID NO:1 or 2.0 mg/kg Dermorphin H

myocardium include reduced infarct siZe, reduced infarct
volume, decreased release of cardiospeci?c troponin I, and

improved ventricular performance.

levels in control rats Were higher than Tn-1 levels in
Dermorphin H SEQ ID NO:2 treated rats at 1 minute and

pressure in mm/Hg in the left ventricle (LVEDP) during

treated animals (about 85%) (open bar) compared to control
animals (about 51%) (solid bar) at 5 min of reperfusion,
While left ventricular functional recovery in Dermorphin H

(n=6). At time points during reperfusion Where samples Were
collected for cTn-1 analysis (1, 60, and 120 min

ventricular function. FIG. 3 is a graph of end diastolic

recovery for animals treated With Dermorphin-H SEQ ID
NO:2 (2.0 mg/kg) Was also increased over control animals
up to 120 min post reperfusion, but the increase Was not

statistically signi?cant.

Dermorphin H SEQ ID NO:2. The solid bars represent
control animals (n=6), the open bars represent Deltorphin A
SEQ ID NO:1 treated animals (n=6), and the hatched bars
represent Dermorphin H SEQ ID NO:2 treated animals

120 minutes folloWing reperfusion. This data indicated that
pretreatment With Deltorphin A SEQ ID NO:1 and Dermor
phin H SEQ ID NO:2 decreased the damage to the
myocardium, as compared to untreated animals.
Deltorphin A SEQ ID NO:1 and Dermorphin H SEQ ID
NO:2 pretreatment also resulted in improved postischemic

mals treated With 2 mg/kg Deltorphin A SEQ ID NO:1 Was

folloWing reperfusion (p=0.01). Left ventricular functional

2.0 mg/kg Deltorphin A SEQ ID NO:1, and 2.0 ml/kg

reperfusion), Tn-1 levels in control rats Were signi?cantly
higher than Tn-1 levels in Deltorphin A SEQ ID NO:1
treated rats at 1 min and 60 minutes folloWing reperfusion,
and Were also higher at 120 min folloWing reperfusion. Tn-1

preischemic developed pressure during reperfusion) for ani
signi?cantly increased over control animals up to 120 min

associated speci?cally With the cardiac muscle, indicates
myocardial damage, likeWise, a decrease in cTn-1 indicates
less cardiac damage.
FIG. 3 is a histogram shoWing cTn-I released during
reperfusion of isolated hearts after 20 min ischemia in rats
treated 24 h prior to ischemia With 0.5 ml saline (control),

ery of developed pressure (DP) in hearts from Deltorphin A
SEQ ID NO:1 and Dermorphin H SEQ ID NO:2 treated
animals remained loWer folloWing the initiation of

40

As another bene?t, Deltorphin A SEQ ID N011 and
Dermorphin H SEQ ID NO:2 may provide a bene?t in

protecting against arrhythmias, similar to the effect of the
o-opioid receptor agonist TAN -67, as reported by Fryer et al.
in 274 J. Biol. Chem. 451—457, 2000, Which is expressly
incorporated by reference herein in its entirety.
45

The invention in its broader aspects is therefore not

limited to the speci?c details, representative apparatus and
method, and illustrative eXamples shoWn and described.
Accordingly, departures may be made from such details
Without departing from the spirit or scope of applicant’s
general inventive concept.

SEQUENCE LISTING

NUMBER OF SEQ ID NOS: 2
SEQ ID NO 1
LENGTH: 7
TYPE: PRT

ORGANISM: Artificial Sequence
FEATURE:

NAME/KEY: MODQRES
LOCATION: (1)...(7)
OTHER

INFORMATION:

synthesized
<400> SEQUENCE: l

Xaa =

D-Met; artificial sequence is completely

US 6,900,178 B2
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-continued
Tyr Xaa Phe His Leu Met Asp
l

5

SEQ ID NO 2
LENGTH: 13
TYPE: PRT

ORGANISM: Artificial Sequence
FEATURE:

NAME/KEY: MODQRES
LOCATION: (1)...(13)
OTHER

INFORMATION:

Xaa =

D-Ala; artificial sequence is completely

synthesized
<400> SEQUENCE: 2

Tyr Xaa Phe Gly Tyr Pro Se]: Gly Glu Ala Lys Lys Ile
l

5

l0

20

group consisting of Deltorphin A SEQ ID NO:1, Dermor
phin H SEQ ID N012, and combinations thereof.

What is claimed is:

1. A method of protecting against ischemia and reperfu

12. The method of claim 11 Wherein the organ is selected
from the group consisting of a heart and a liver.

sion injury in a mammal comprising administering a com

pound selected from the group consisting of Deltorphin A
SEQ ID NO:1, Dermorphin H SEQ ID N012, and combi

25

14. The method of claim 11 Wherein Dermorphin H SEQ

able formulation and an effective amount.

ID NO:2 is at a concentration of about 100 pm in the

2. The method of claim 1 Wherein administration is prior

solution.
15. A method for reducing effects of ischemia in a
mammal comprising administering an effective amount of a

to onset of ischemia.

3. The method of claim 2 Wherein administration is about
24 hours prior to onset of ischemia.
4. The method of claim 1 Wherein Deltorphin A SEQ ID
NO:1 and Dermorphin H SEQ ID NO:2 are administered as

compound selected from the group consisting of Deltorphin

a solution.

5. The method of claim 1 Wherein Deltorphin A SEQ ID
NO:1 and Dermorphin H SEQ ID NO:2 are administered

35

parenterally.
6. The method of claim 1 Wherein Deltorphin A SEQ ID
NO:1 and Dermorphin H SEQ ID NO:2 are administered at

a concentration of about 2 mg/kg of body Weight of the
mammal.
7. The method of claim 1 Wherein Deltorphin A SEQ ID
NO:1 and Dermorphin H SEQ ID NO:2 are administered to

40

19. A method of protecting a mammal against cardiac

arrhythmias comprising administering a compound selected
from the group consisting of Deltorphin A SEQ ID NO:1,
45

acceptable formulation.
20. A solution to preserve viability of an isolated organ

10. The method of claim 9 Wherein the compound is
11. A method to preserve an isolated organ comprising
exposing the organ to a solution comprising a preservative
and an effective amount of a compound selected from the

Dermorphin H SEQ ID NO:2 and combinations thereof to
the mammal in an effective amount and a pharmaceutically

nitric oxide synthase.

arginine hydrochloride.

A SEQ ID NO:1, Dermorphin H SEQ ID NO:2 and com
binations thereof in a pharmaceutically acceptable carrier to
the mammal.
16. The method of claim 15 Wherein said compound is
administered prior to ischemia.
17. The method of claim 15 Wherein said compound is
administered concurrently With onset of ischemia.
18. The method of claim 15 Wherein said compound is
administered after one hour of cerebral ischemia.

protect against myocardial ischemia.
8. The method of claim 1 Wherein the formulation further
includes a compound having an anti-ischemic effect.
9. The method of claim 8 Wherein the compound affects

13. The method of claim 11 Wherein DeltorphinASEQ ID
NO:1 is at a concentration of about 100 pM in the solution.

nations thereof to the mammal in a pharmaceutically accept

50

comprising a compound selected from the group consisting
of Deltorphin A SEQ ID NO:1, Dermorphin H SEQ ID
NO:2, and combinations thereof at a concentration effective

to protect the organ from ischemic injury.
*

*

*

*

*
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